Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)
Clinical trial NCT02658981 · COMPLETED
Trial details
- NCT number
- NCT02658981
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-08-24
- Primary completion
- 2022-04-30
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.